PMV Pharmaceuticals Inc. (NASDAQ:PMVP) currently has a daily average trading volume of 628.78K but it saw 438968 shares traded on Wednesday. With a market cap of 473.09M USD, stock’s current market price of $10.07 came falling about -1.76 while comparing to the previous closing price of $10.25. In past 52 weeks, the stock remained buoying in the range of price level as high as $25.10 and as low as $8.99. In the recent trading on the day, stock has struck highest price mark of $10.48 while lowest mark touched by it was $9.81.
Taking a look at 20-day trading activity of PMV Pharmaceuticals Inc. (PMVP) gives us an average price of $10.99, while its current price level is -59.88% below from 52-week high level whereas it is 12.01% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $11.65 while that of 200 days or SMA-200 reads an average of $14.52. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.63% during that period while stretching the period over a month that increases to 8.02%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 40.93 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Oppenheimer which upgraded the stock as “Outperform” in its note to investors issued on March 02, 2022, recommending a price target of $30 for it. Goldman upgraded its recommendation for the stock as a “Buy” from “Neutral” on September 22, 2021 while assigning a price target range of $35-$43.
Over the week, PMVP’s stock price is moving -2.14% down while it is -16.57% when we observe its performance for the past one month. Year-to-date it is -56.41% down and over the past year, the stock is showing a downside performance of -59.46%.
The latest quarterly earnings report issued by the company was for quarter ended 6/29/2022, when its quarterly earnings per share (EPS) of -$0.38 beat the consensus estimate of -$0.41 for the same. For PMVP, analysts are forecasting an EPS-growth rate of -30.50% for current year and estimate for EPS growth in next year is -16.20%.
Currently, PMV Pharmaceuticals Inc.’s total number of outstanding shares is 45.62M with 2.07% of that held by the insiders while 135.57% of its common stock has been owned by the institutions. Company’s return on equity (ROE) at -25.40%. Stock has a price to book (P/B) ratio of 1.76. Its return on asset (ROA) is -23.50% on average.
A filing at the U.S. Securities and Exchange Commission revealed that SPDR S&P Biotech ETF came shrinking its share ownership by 0.56% in the PMV Pharmaceuticals Inc. (PMVP) increasing its stake to 7.48% with control over 18860.0 shares in the company. In the most recent quarter, JPMorgan Small Cap Growth Fund came cutting its stake by -0.75% in the company and now holds 1.28 million or 2.81% of the company’s stake having worth of about 15.79 million.